综合医院心血管疾病与抑郁焦虑的相关研究进展

杨学平; 何茹

doi:10.16766/j.cnki.issn.1674-4152.002338

综合医院心血管疾病与抑郁焦虑的相关研究进展

doi: 10.16766/j.cnki.issn.1674-4152.002338

杨学平,
何茹^,

中国医科大学人民医院辽宁省人民医院心理科，辽宁沈阳 110016

详细信息

通讯作者:
何茹，E-mail：syheru@163.com

中图分类号: R54 R395
计量
- 文章访问数: 232
- HTML全文浏览量: 125
- PDF下载量: 24
- 被引次数: 0
出版历程
- 收稿日期: 2020-07-06
- 网络出版日期: 2022-03-04

Advances in the associated study of cardiovascular disease with depression and anxiety in general hospitals

YANG Xue-ping,
HE Ru^,

Psychology Department, the People's Hospital of China Medical University, Shenyang, Liaoning 110016, China

摘要

摘要: 在综合医院里，心血管疾病是一类发生率和致死率较高的疾病，其风险因素和疾病预防一直是人们研究的重点。近年来，因心理因素如抑郁焦虑对心血管疾病患者的重要影响，使作为可控因素的心理因素成为研究关注的重点。抑郁焦虑可以增加心血管疾病的发生率，抑郁焦虑的人群出现心血管疾病的几率要比正常人群高，并且可以加重心血管疾病的不良后果如增加致死率等。同时，心血管疾病的患者也更容易出现抑郁焦虑。对于心血管疾病患者来说，抑郁焦虑的发生与多方面因素有关，如与疾病相关的事件可以作为应激因素导致抑郁焦虑的发生；在疾病康复期，患者体育活动、生活质量等水平的不同、后期可能出现的认知障碍，也与抑郁焦虑的发生有关。而对于心血管疾病患者合并抑郁焦虑的治疗，在针对抑郁焦虑的治疗上，可考虑应用心理治疗及药物治疗等措施。基于心理治疗的有效性及安全性，其也成为近年来的治疗趋势，不过具体的实施形式则要根据具体情况制定。对于药物治疗，抗抑郁抗焦虑药物如选择性五羟色胺再摄取抑制剂的应用能明显改善抑郁焦虑情绪，同时可以降低发生心血管事件的风险。但是，药物的不恰当应用也可能会增加心血管疾病的发生。所以，药物的使用一定要经过科学评估后，慎重选择和正确应用。
- 综合医院 /
- 抑郁焦虑 /
- 心血管疾病
Abstract: Cardiovascular disease (CVD) has high incidence and fatality rate in general hospitals, and its risk factors and disease prevention have been the focus of research. In recent years, because of the important influence of psychological factors, such as depression anxiety on CVD patients, psychological factors as controllable factors have become the focus of research. Depression and anxiety can increase the incidence of CVD. People with depression and anxiety are likely to develop CVD than normal. Depression and anxiety can exacerbate adverse consequences of CVD, such as increased fatality. Patients with CVD can also develop depression and anxiety. For patients with CVD, the occurrence of depression and anxiety is related to various factors. For example, disease-related events can be used as a stress factor to cause depression and anxiety. During the recovery period of the disease, different levels of physical activity, quality of life and other possible cognitive impairment can also be associated with depression and anxiety. Psychological therapy and drug therapy can be considered as treatment for CVD patients combined with depression and anxiety. Given the effectiveness and safety of psychotherapy, it has also become a trend of treatment in recent years, but the specific form of implementation should be based on a specific situation. For medications, the use of anti-depressants, such as selective serotonin reuptake inhibitors, can significantly improve depression and anxiety and reduce the risk of cardiovascular events. However, inappropriate drug use may also increase the risk of CVD. Therefore, the use of drugs must be scientifically evaluated, carefully selected and correctly applied.
- General hospital /
- Depression and anxiety /
- Cardiovascular disease

HTML全文

参考文献(42)

[1]	FARNAZ S, PARVANE S, ALIREZA M, et al. Dietary glycemic index, glycemic load, and risk of mortality from all causes and cardiovascular diseases: A systematic review and dose-response meta-analysis of prospective cohort studies[J]. Am J Clin Nutr, 2019, 110(4): 921-937. doi: 10.1093/ajcn/nqz061
[2]	HSU C N, LU P C, LO M H, et al. The association between nitric oxide pathway, blood pressure abnormalities, and cardiovascular risk profile in pediatric chronic kidney disease[J]. Int J Mol Sci, 2019, 20(21): 5301. doi: 10.3390/ijms20215301
[3]	HADIS M, NAZLI N, BAGHER L, et al. Association of dietary acid load with cardiovascular risk factors and the prevalence of metabolic syndrome in Iranian women: A cross-sectional study[J]. Nutrition, 2019, 67-68: 110570. doi: 10.1016/j.nut.2019.110570
[4]	CUI K W, SONG R X, XU H, et al. Association of cardiovascular risk burden with risk and progression of disability: Mediating role of cardiovascular disease and cognitive decline[J]. J Am Heart Assoc, 2020, 9(18): 017346.
[5]	KYROU I, KOLLIA N, PANAGIOTAKOS D, et al. Association of depression and anxiety status with 10-year cardiovascular disease incidence among apparently healthy Greek adults: The ATTICA Study[J]. Eur J Prev Cardiol, 2017, 24(2): 145-152. doi: 10.1177/2047487316670918
[6]	CASE S M, SAWHNEY M, STEWART J C. Atypical depression and double depression predict new-onset cardiovascular disease in U.S. adults[J]. Depress Anxiety, 2018, 35(1): 10-17. doi: 10.1002/da.22666
[7]	MAL K, AWAN I D, RAM J, et al. Depression and anxiety as a risk factor for myocardial infarction[J]. Cureus, 2019, 11(11): e6064.
[8]	SVERRE E, PEERSEN K, WEEDON-FEKJÆR H, et al. Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population[J]. BMC Cardiovasc Disord, 2020, 20(1): 61. doi: 10.1186/s12872-020-01368-6
[9]	GUSTAD L T, BJERKESET O, STRAND L B, et al. Cardiac function associated with previous, current and repeated depression and anxiety symptoms in a healthy population: The HUNT study[J]. Open Heart, 2016, 3(1): e000363. doi: 10.1136/openhrt-2015-000363
[10]	GARCIA R G, MARECKOVA K, HOLSEN L M, et al. Impact of sex and depressed mood on the central regulation of cardiac autonomic function[J]. Neuropsychopharmacol, 2020, 45(8): 1280-1288. doi: 10.1038/s41386-020-0651-x
[11]	HAMIEH N, MENETON P, ZINS M, et al. Hostility, depression and incident cardiac events in the GAZEL cohort[J]. J Affect Disord, 2020, 266: 381-386. doi: 10.1016/j.jad.2020.01.164
[12]	AOKI T, YAMAMOTO Y, SHIMIZU S, et al. Physical multimorbidity patterns and depressive symptoms: A nationwide cross-sectional study in Japan[J]. Fam Med Community Health, 2020, 8(1): e000234. doi: 10.1136/fmch-2019-000234
[13]	BRUYNINX G, GRENIER J, GREENMAN P S, et al. Prevalence of symptoms of anxiety disorders and depression in cardiac rehabilitation patients in an academic hospital: A case study[J]. Psychiatr Q, 2021, 92(3): 273-287.
[14]	ARREBOLA-MORENO M, PETROVA D, GARRIDO D, et al. Psychosocial markers of pre-hospital decision delay and psychological distress in acute coronary syndrome patients[J]. Br J Health Psychol, 2020, 25(2): 305-323. doi: 10.1111/bjhp.12408
[15]	皮静虹, 付琼芬, 陈文敏, 等. Stanford A型主动脉夹层患者围术期焦虑抑郁状况及影响因素[J]. 昆明医科大学学报, 2020, 41(3): 101-105. doi: 10.3969/j.issn.1003-4706.2020.03.020
[16]	TULLY P J, WINEFIELD H R, BAKER R A, et al. Depression, anxiety and major adverse cardiovascular and cerebrovascular events in patients following coronary artery bypass graft surgery: A five year longitudinal cohort study[J]. Biopsychosoc Med, 2015, 9: 14. doi: 10.1186/s13030-015-0041-5
[17]	SHAO M, LIN X, JIANG D, et al. Depression and cardiovascular disease: Shared molecular mechanisms and clinical implications[J]. Psychiatry Res, 2020, 285: 112802. doi: 10.1016/j.psychres.2020.112802
[18]	TOKGÖZOĜLU L, OKUTUCU S, KAYA E B, et al. Physical inactivity and low quality of life of Turkish women after hospitalization for coronary heart disease: Inferences from EUROASPIRE Ⅲ[J]. Turk Kardiyol Dern Ars, 2016, 44(6): 488-497.
[19]	GALLAGHER R, WOOLASTON A, TOFLER G, et al. Cognitive impairment and psychological state in acute coronary syndromepatients: A prospective descriptive study at cardiac rehabilitation entry, completion and follow-up[J]. Eur J Cardiovasc Nurs, 2020, 20(1): 147451512093310.
[20]	CELANO M C, MILLSTEIN A R, BEDOYA A C, et al. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis[J]. Am Heart J, 2015, 170(6): 1105-1115. doi: 10.1016/j.ahj.2015.09.013
[21]	WORCESTER M U, GOBLE A J, ELLIOTT P C, et al. Mild depression predicts long-term mortality after acute myocardial infarction: A 25-year follow-up[J]. Heart Lung Circ, 2019, 28(12): 1812-1818. doi: 10.1016/j.hlc.2018.11.013
[22]	YEH T C, KAO L C, TZENG N S, et al. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine andparoxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA)[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2016, 64: 60-67. doi: 10.1016/j.pnpbp.2015.07.007
[23]	PALACIOS J E, KHONDOKER M, ACHILLA E, et al. A single, one-off measure of depression and anxiety predicts future symptoms, higher healthcare costs, and lower quality of life in coronary heart disease patients: Analysis from a multi-wave, primary care cohort study[J]. PLoS One, 2016, 11(7): e0158163. doi: 10.1371/journal.pone.0158163
[24]	XIAO J, KONG T Z, MCWHINNIE C M, et al. The tripartite model for assessing symptoms of depression and anxiety: Psychometric properties of the Chinese version of the mood and anxiety symptoms questionnaire in patients with essential hypertension[J]. J Cardiovasc Nurs, 2015, 30(6): 522-528. doi: 10.1097/JCN.0000000000000193
[25]	LILAMAND M, SAINTOUT M, VIGAN M, et al. Quality of life, physical performance and nutritional status in older patients hospitalized in a cardiology department[J]. J Geriatr Cardiol, 2020, 17(7): 410-416.
[26]	DEMPE C, JVNGER J, HOPPE S, et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease[J]. J Psychosom Res, 2013, 74(2): 122-127. doi: 10.1016/j.jpsychores.2012.12.003
[27]	HERBSLEB M, SCHUMANN A, LEHMANN L, et al. Cardio-respiratory fitness and autonomic function in patients with major depressive disorder[J]. Front Psychiatry, 2020, 10: 980. doi: 10.3389/fpsyt.2019.00980
[28]	PAPAZISIS A, KORELI A, MISOURIDOU E. Heavy smoking is associated with low depression and stress: A smokers' paradox in cardiovascular disease?[J]. Mater Sociomed, 2019, 31(4): 268-272. doi: 10.5455/msm.2019.31.268-272
[29]	GRECH M, TURNBULL D A, WITTERT G A, et al. Identifying the internalizing disorder clusters among recently hospitalized cardiovascular disease patients: A receiver operating characteristics study[J]. Front Psychol, 2019, 10: 2829. doi: 10.3389/fpsyg.2019.02829
[30]	CELANO C M, HEALY B, SUAREZ L, et al. Cost-effectiveness of a collaborative care depression and anxiety treatment program in patients with acute cardiac illness[J]. Value Health, 2016, 19(2): 185-191. doi: 10.1016/j.jval.2015.12.015
[31]	SALZWEDEL A, KORAN I, LANGHEIM E, et al. Patient-reported outcomes predict return to work and health-related quality of life six months after cardiac rehabilitation: Results from a German multi-centre registry (OutCaRe)[J]. PLoS One, 2020, 15(5): e0232752. doi: 10.1371/journal.pone.0232752
[32]	GAO W Q, WANG F Z, WANG S N, et al. Effect of cognitive behavioral therapy for heart failure: A systematic review protocol of randomized controlled trial[J]. Medicine(Baltimore), 2019, 98(33): e16803.
[33]	RAFANELLI C, GOSTOLI S, BUZZICHELLI S, et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: A randomized controlled trial (TREATED-ACS study)[J]. Psychother Psychosom, 2020, 89(6): 1-12.
[34]	刘霞, 张巧利, 吕安康. 心血管疾病患者合并心理障碍的发病情况及干预措施研究[J]. 解放军预防医学杂志, 2020, 38(5): 80-82. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYX202005028.htm
[35]	CHANG Z X, GUO A Q, ZHOU A X, et al. Nurse-led psychological intervention reduces anxiety symptoms and improves quality of life following percutaneous coronary intervention for stable coronary artery disease[J]. Aust J Rural Health, 2020, 28(2): 124-131. doi: 10.1111/ajr.12587
[36]	SONG X Q, SONG J X, SHAO M J, et al. Depression predicts the risk of adverse events after percutaneous coronary intervention: A meta-analysis[J]. J Affect Disord, 2020, 266: 158-164. doi: 10.1016/j.jad.2020.01.136
[37]	FERNANDES N, PRADA L, ROSA M M, et al. The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: Systematic review and meta-analysis[J]. Clin Res Cardiol, 2021, 110(2): 183-193. doi: 10.1007/s00392-020-01697-8
[38]	王启辉, 陈丽霞, 王思洋, 等. 草酸艾司西酞普兰对冠心病伴焦虑抑郁患者负性情绪及心功能的影响[J]. 实用心脑肺血管病杂志, 2019, 27(11): 85-88. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL201911023.htm
[39]	OSVALDO P A, ANDREW H F, GRAEME J H, et al. Depression, antidepressants and the risk of cardiovascular events and death in older men[J]. Maturitas, 2019, 128: 4-9. doi: 10.1016/j.maturitas.2019.06.009
[40]	HEDRICK R, KOROURI S, TADROS E, et al. The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: A systematic review[J]. Drugs Context, 2020. DOI: 10.7573/dic.2020-5-4.
[41]	BIFFI A, REA F, SCOTTI L, et al. Antidepressants and the risk of cardiovascular events in elderly affected by cardiovascular disease: A real-life investigation from Italy[J]. J Clin Psychopharmacol, 2020, 40(2): 112-121. doi: 10.1097/JCP.0000000000001189
[42]	强晓玲, 王海霞, 朱品, 等. 盐酸舍曲林联合重复经颅磁刺激治疗心血管疾病伴发抑郁的临床研究[J]. 临床内科杂志, 2019, 36(6): 423-424. doi: 10.3969/j.issn.1001-9057.2019.06.020